On the stock market since 2015, it operates in the world of health and science. It has 506 employees. Now — the numbers.
This is an established company with proven profits.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
No real growth (-1% a year). Red columns mark years that ended in a loss.
If every debt were paid off today, $11.9M would still be left in the vault — a solid cushion for hard times.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 425% — that slice of every sale is the company’s cushion in hard quarters.
There is $26.0M in the vault; even if every debt were paid off, $11.9M would remain.
The average analyst price target is $2.83 — 55,390% above today’s price.
The stock sits at $0.0051. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
Over the last 3 years, sales fell about 40% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
On our five-subject report card, ADAPY sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: ADAPY is an established business that has proven its profits for years. The real debate isn’t the quality of the business — it’s whether the price paid for the stock is too high.